GeoVax Labs has amended a previously executed Patent and Biological Materials License Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, in support of GeoVax’s development of a vaccine against SARS-CoV-2. The amendment expands GeoVax’s commercial license to include Mpox and smallpox as additional indications. The License Agreement, as amended, allows GeoVax to use these materials and patent rights owned by agencies of the United States Department of Health and Human Services in combination with the Company’s proprietary technology for the creation of preventive Modified Vaccinia Ankara Virus-Virus Like Particle vaccines that prime and/or boost the immune system against SARS-CoV-2 as well as Mpox and/or smallpox. Financial terms of the License Agreement were not disclosed.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GOVX:
- GeoVax to Participate in Upcoming December Investor Events
- GeoVax Labs announces COVID-19 vaccine data to be presented at WVC
- GeoVax Labs announces presentation of preclinical data for GEO-CM02
- GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update
- GeoVax Labs reports Q3 EPS (32c), consensus (24c)